Guest post by Lucia Tamayo Del Portillo*
After causing major buzz in 2017 due to the decision of the patent interference procedure before the United States Patent and Trademark Office (USPTO) which is currently under review in Federal Court, the Crispr Cas9 patent battle enters into 2018 with another shocking decision, this time rendered by the opposition division of the European Patent Office (EPO).
As readers may recall, Crispr Cas9 is a gene editing tool that allows scientists to manipulate DNA of living organisms in a cost-effective manner with accurate precision and the possibility to add, amend or delete parts of DNA sequences. The technology has multiple applications in different industries, with, of course, human health being the most promising and profitable one. Continue reading “Latest update on the crispr cas9: the patent battle continues in Europe”